Mr Jeremy Ockrim is honorary senior lecturer at UCL and consultant urological surgeon in female and reconstructive surgery at University College Hospital, London.
Mr Ockrim trained in Glasgow before moving to Imperial College, London to complete his postgraduate thesis in 1999. He has an honours degree in immunology; and his MD thesis is based on the utility of oestrogens in prostate cancer. His clinical fellowship was undertaken at the Royal Melbourne Hospital, Australia. Mr Ockrim trained in female and reconstructive urology at the Institute of Urology, University College Hospital, and was appointed to this substantive consultant post in November 2008. The Institute of Urology offers tertiary expertise in male and female reconstructive urology to urologists and urogynaecologists nationwide. He continues his academic and teaching links at Imperial College and University College London, and has written extensively on lower urinary tract dysfunction, urodynamics, detrusor overactivity, fistulae, diverticula and tape surgery.
His practice specialises in the treatment of bladder dysfunction, male and female incontinence including colposuspension, TVT/TOT, male sling, artificial urinary sphincter implantation, urinary fistulae and diverticula surgery, prolapse repair, bladder augmentation, bladder replacement and both continent and incontinent urinary diversion. He has particular interest in managing bladder overactivity and pain syndromes. This includes medical therapy, acupuncture, Botox and neuromodulation.
He is the clinical lead for sacral nerve neuromodulation at University College Hospital, and is one of the first providers of sacral nerve stimulation to manage urgency, incontinence and pain syndromes in the United Kingdom.
Mr Ockrim is a member of the British Association of Urological Surgeons (BAUS), European Association of Urology, Royal College of Surgeons of Edinburgh, Royal Society of Medicine, British Medical Association and is assistant editor of the Central European Journal of Urology.
- Male and female incontinence
- Male sling
- Artificial urinary sphincter implantation
- Urinary fistulae and diverticula surgery
- Prolapse repair
- Anterior and posterior repair
- Bladder reconstruction
- Bladder augmentation
- Bladder replacement and both continent and incontinent urinary diversion
- Bladder overactivity and pain syndromes
- Medical therapy
- Sacral neuromodulation (nerve stimulators)
A tertiary experience of urethral diverticulectomy: diagnosis, imaging and surgical outcomes Ockrim JL, Shah PJR, Greenwell TJ. BJU Int. 2009 Jun;103(11):1550-4.
Snail expression is an independent predictor of tumor recurrence in superficial bladder cancers. Bruyere F, Namdarian B, Corcoran NM, Pedersen J, Ockrim J, Voelzke BB, Mete U, Costello AJ, Hovens CM.Urol Oncol. 2009 Jan 20. [Epub ahead of print]
A tertiary experience of vesico-vaginal and urethro-vaginal fistula repair: factors predicting success Ockrim JL, Greenwell TJ, Wood DN, Foley CL, Shah PJR. BJU Int. 2009 Apr;103(8):1122-6. Epub 2009 Jan 20.
Tension free transvaginal (TVT) and transobturator (TOT) tape procedures in women with multiple failed incontinence procedures or complex urogynaecological intervention. Ockrim JL, Shah PJR, Greenwell TJ. BJMSU 2008 Sept;1(2):67-74
Considering the long-term impact of androgen deprivation therapy for prostate cancer: is it timely to reconsider options? Ockrim JL and Abel PD BMJ Editorial 2008;337:a1361 A
urora Kinase B is an independent protective factor in superficial bladder tumours with a dysfunctional G1 checkpoint. Bruyere F, Corcoran NM, Berdjis N, Namdarian B, Pedersen J, Ockrim JL, Voelzke BB, Costello AJ, Hovens CM. BJU Int. 2008 Jul;102(2):247-52. Epub 2008 Jul 1.
Therapy Insight: parenteral estrogen treatment for prostate cancer-a new dawn for an old therapy Ockrim JL, Lalani E, Abel PD Nat Clin Pract Oncol. 2006 Oct;3(10):552-63. Review.
Changes in vascular flow during transdermal estradiol therapy for prostate cancer: the dichotomy of early versus delayed effect? Ockrim JL, Lalani E, Aslam M, Stansfield H, Kakkar AK, Abel PD. BJU Int. 2006 Mar;97(3):498-504.
Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism. Ockrim JL, Lalani E, Kakkar AK, Abel PD. J Urol. 2005 Aug;174(2):527-33
Variability of detrusor overactivity on repeated filling cystometry in men with urge symptoms: comparison with spinal cord injury patients. Ockrim JL, Laniado ME, Khoubehi B, Renzetti R, Finazzi Agrò E, Carter S and Tubaro A. BJU Int. 2005 Mar;95(4):587-90.
Transdermal estradiol improves bone density when used as single agent therapy for prostate cancer Ockrim JL, Lalani E, Banks LM, Svensson WE, Blomley MJ, Patel S, Laniado ME, Carter S and Abel PD J Urol. 2004 Dec;172(6, Part 1 of 2):2203-2207.
Serum prostate-specific antigen to predict the presence of bladder outlet obstruction in men with urinary symptoms. Laniado ME, Ockrim JL, Marronaro A, Tubaro A, Carter S. BJU Int. 2004 Dec;94(9):1283-6.
Transdermal estradiol therapy for advanced prostate cancer--forward to the past? Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD.J Urol. 2003 May;169(5):1735-7.
A probability based system for combining simple office parameters as a predictor of bladder outflow obstruction. Ockrim JL, Laniado ME, Patel A, Tubaro A, St Clair Carter S. J Urol. 2001 Dec;166(6):2221-5